OOIR: Observatory of International Research

Papers

(The TQCC of Immunotherapy is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors	169
Pasotuxizumab, a BiTE^® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings	70
Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens	66
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait	64
A global picture: therapeutic perspectives for COVID-19	54
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis	35
Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma	34
Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?	34
Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report	34
Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i)	29
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins	28
Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis	27
Therapeutics to tackle Omicron outbreak	27
Interferons: role in cancer therapy	27
Systemic immune–inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis	26
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma	26
Tumor cell-based vaccine: an effective strategy for eradication of cancer cells	25
Immunotherapy for gastric cancer: a 2021 update	25
The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy	25
Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia	24
Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma	24
TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases	24
Antimicrobial/anticancer peptides: bioactive molecules and therapeutic agents	23
Sublingual immunotherapy for food allergy and its future directions	22
Efficacy of immune checkpoint inhibitors and age in cancer patients	22

Concurrent Vogt–Koyanagi–Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma	21
Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?	20
Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy	20
Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection	19
Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function	19
Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer	19
Targeted allergen-specific immunotherapy within the skin improves allergen delivery to induce desensitization to peanut	19
COVID-19: the use of immunotherapy in metastatic lung cancer	18
The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease	17
Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment	17
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019	16
Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma	16
Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations	16
Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma	16
Atherosclerosis: immunopathogenesis and strategies for immunotherapy	16
Obesity, COVID-19 and immunotherapy: the complex relationship!	16
Cost–effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC	16
Early change in peripheral CD4⁺ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer	15
Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy	15
Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report	15
Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy	15
Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment	15
Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward	15
PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare	15
Non-coding RNA and immune-checkpoint inhibitors: friends or foes?	15
Immunity to glycan α-Gal and possibilities for the control of COVID-19	15
Romosozumab in the treatment of osteoporosis	14
MUC1 antibody-based therapeutics: the promise of cancer immunotherapy	14
Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature	13
Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis	13
Efficacy of immunotherapy inKRAS-mutant non-small-cell lung cancer with comutations	13
Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer	13
Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer	12
Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19	12
Ex vivo-generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems	12
Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment	12
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy	12
Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis	12
Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination	12
Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report	12
Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application	12
Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy	12
Emerging advances in cationic liposomal cancer nanovaccines: opportunities and challenges	12
Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma	11
Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis	11
Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review	11
Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases	11
Immunotherapy in hematological malignancies: recent advances and open questions	11
A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review	11
Guselkumab in the treatment of moderate-to-severe plaque psoriasis	11

Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR	10
The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases	10
Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma	10
Immunotherapy in psoriasis	10
A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma	10
A review of secukinumab in psoriasis treatment	10
Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study	10
Immunotherapy for cholangiocarcinoma: a 2021 update	10
Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report	10
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)	9
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases	9
COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy	9
Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1	9
Dupilumab use in atopic dermatitis and beyond in skin diseases	9
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison	9
The immunotherapy revolution in genitourinary malignancies	9
Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis	9
Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients	9
Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy	9
Safety of semi-depot house dust mite allergen extract in children and adolescents with allergic rhinitis and asthma	9
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases	9
Neurological adverse events following CAR T-cell therapy: a real-world analysis	9
Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma	8
PD-1,CTLA4,PD-L1andPD-L2DNA methylation in papillary thyroid carcinoma	8
Differences between diffuse idiopathic skeletal hyperostosis and spondyloarthritis	8
Obesity and immunotherapy: the surprisingly positive association!	8
Asthma immunotherapy and treatment approaches with mesenchymal stem cells	8
Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors	8
Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers	8
Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer	7
Eculizumab in the treatment of neuromyelitis optica spectrum disorder	7
Cost–effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer	7
Immunology of osteoporosis: relevance of inflammatory targets for the development of novel interventions	7
Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature	7
HLA loss of heterozygosity-mediated discordant responses to immune checkpoint blockade in squamous cell lung cancer with renal metastasis	7
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice	7
Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up	7
Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis	7
Immunoregulatory T cell epitope peptides for the treatment of allergic disease	7
Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8⁺T cells in lung cancer	7
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence	7
Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy	7
Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma	7
Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report	7
Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review	7
Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy	7
Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity	7
Treatment of EAE mice with Treg, G-MDSC and IL-2: a new insight into cell therapy for multiple sclerosis	7
Hurdles for the wide implementation of photoimmunotherapy	7
Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians	7
Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review	7
Pembrolizumab-associated erythema nodosum in the treatment of metastatic melanoma	7
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary	7
Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases	7
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors	6
GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey	6
Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma	6
Delayed immune-related neutropenia with hepatitis by pembrolizumab	6
Therapeutic cancer vaccine therapy for acute myeloid leukemia	6
Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report	6
Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research	6
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy	6
Lichenoid drug eruption on the lower lip caused by anti-PD-1 monoclonal antibody: a case report and literature review	6
Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer	6
The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't	6
Severe chronic nonlichenoid oral mucositis in pembrolizumab-treated patients: new cases and a review of the literature	6
Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review	6
Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review	6
Peptide vaccine with glucopyranosyl lipid A–stable oil-in-water emulsion for patients with resected melanoma	6
Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review	6
Small-cell breast carcinoma with response to atezolizumab: a case report	6
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland	6
Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis	6
Designing novel immunocombinations in metastatic renal cell carcinoma	6
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab	6